2017
Gender differences in the real-world effectiveness of smoking cessation medications: Findings from the 2010–2011 Tobacco Use Supplement to the Current Population Survey
Smith PH, Zhang J, Weinberger AH, Mazure CM, McKee SA. Gender differences in the real-world effectiveness of smoking cessation medications: Findings from the 2010–2011 Tobacco Use Supplement to the Current Population Survey. Drug And Alcohol Dependence 2017, 178: 485-491. PMID: 28715776, PMCID: PMC6779031, DOI: 10.1016/j.drugalcdep.2017.05.046.Peer-Reviewed Original ResearchConceptsTransdermal nicotine patchUnassisted quit attemptsClinical trial dataTobacco Use SupplementQuit attemptsTrial dataClinical trial findingsReal-world effectivenessSample of smokersGender differencesRelevant gender differencesCessation optionsCessation medicationsCessation pharmacotherapyNicotine patchMedication interactionsSmoking cessationPotential confoundersTrial findingsVareniclineComparative effectivenessPropensity scoreCross-sectional dataWomenMedications
2010
Exploring the impact of gender and reproductive status on outcomes in a randomized clinical trial of naltrexone augmentation of nicotine patch
Epperson CN, Toll B, Wu R, Amin Z, Czarkowski KA, Jatlow P, Mazure CM, O’Malley S. Exploring the impact of gender and reproductive status on outcomes in a randomized clinical trial of naltrexone augmentation of nicotine patch. Drug And Alcohol Dependence 2010, 112: 1-8. PMID: 20561758, PMCID: PMC2946976, DOI: 10.1016/j.drugalcdep.2010.04.021.Peer-Reviewed Original ResearchConceptsPlacebo groupStudy completersNaltrexone doseClinical trialsContinuous abstinenceOral naltrexone treatmentNicotine patch therapyNicotine replacement therapyInteractive voice responseRandomized clinical trialsMenstrual cycle statusEffect of doseNaltrexone augmentationNaltrexone groupAdverse eventsNaltrexone treatmentNicotine patchPatch therapyReplacement therapyQuit dayWeek 1AbstinenceDoseWomenLess adherent